aCcelerated erAS carE for minor and major liver surgery: the CHASE liver study

Conditions: Liver malignancies
Liver neoplasms
Liver tumors
10019815
10019818

Registration Number: NL-OMON56942

Lead Sponsor: Zuyderland Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 40

Inclusion Criteria

- Signed informed consent;
- Is >= 18 years <= 85;
- BMI <= 35 kg/m2;
- ASA I-III;
- Diagnosed with liver malignancy;
- Is scheduled to undergo elective laparoscopic liver resection, whether or not
combined with ablation
- Readily available ambulant care provided by an adult family member for the
first 24 hours after discharge;
- Proficient in Dutch language and writing;
- Patient is adequately reachable by phone.

Exclusion Criteria

- ASA classification > 3;
- Subjects undergoing rehepatectomy
- Subjects who have limited mobility and/or need to be aided/assisted when
mobilizing;
- Subjects with a history of active pulmonary infection, any other active
infection, any uncontrolled medical disease;
- Subjects with (any form of) liver cirrhosis
- Subjects with a contraindication for oral NSAIDs;
- Subjects with a contraindication for spinal anesthesia;
- Subjects requiring parenteral nutrition prior to surgery;
- Subjects receiving an ostomy;
- Subjects who experience complications preoperatively;
- Subjects who are mentally incompetent, challenged or requiring aid with daily
life activities.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Rate of the successful and safe application of the accelerated recovery<br /><br>protocol for patients undergoing elective liver surgery. Success rate<br /><br>(feasibility) will be measured in length of hospital stay (LOS). Success is<br /><br>defined as discharge on POD1 after a minor liver resection and on POD2-3 after<br /><br>major liver resection discharge. Safety will be measured with rate of<br /><br>readmission and serious adverse events (Clavien Dindo >=3b) within 90 days<br /><br>postoperatively. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>• Postoperative complications within 90 days<br /><br>• Postoperative mortality within 90 days<br /><br>• Difference between achievement of functional recovery and actual discharge<br /><br>date<br /><br>• Patient satisfaction evaluation form<br /><br>• Demographic parameters<br /><br>• Disease related demographics<br /><br>• Comorbidities</p><br>